#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Oropharyngeal cancer recurrent Hereditary ataxia Gastric cancer Neurotrophic keratopathy Congenital disorder of glycosylation Retinoblastoma Hypoparathyroidism Acute graft versus host disease in skin Short stature homeobox gene mutation Duchenne muscular dystrophy Carcinoid syndrome Follicular lymphoma stage II Pleomorphic liposarcoma Bronchiolitis Partial lipodystrophy More trials…

    Learn about Rare Diseases

    Haemophilia B with anti factor IX – Trials in Disease Rhabdomyosarcoma recurrent – Trials in Disease Glycogen storage disease type V – Diagnostics Ocular melanoma – Basic Information Niemann-Pick disease Ocular melanoma – Life with Disease Hypereosinophilic syndrome – Trials in Disease Mastocytosis – Treatment Aicardi-Goutieres syndrome – Treatment Friedreich’s ataxia – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Etamsylate L-Threonine Glyceryl Trinitrate Zipalertinib Caspofungin Minocycline Hydrochloride Cefotaxime Sodium Tedizolid Phosphate Tarlatamab Estradiol Hemihydrate Glofitamab Denosumab Mps-200 ATIRMOCICLIB IG-TREGS Istradefylline Cdr132L Sodium Blu-222 D5-Ethyl-Beta-D-Glucuronide Dexamethasone Isonicotinate More therapies…

    Learn about Your Condition

    Yellow fever Myocardial infarction Diabetes mellitus Peritoneal abscess Naevoid melanoma Hepatic neoplasm Squamous cell carcinoma Psychogenic seizure Progressive supranuclear palsy Anal incontinence Thalassaemia alpha Atrial septal defect B-cell lymphoma Familial mediterranean fever Prostate cancer metastatic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone-dependent prostate cancer

  • Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Apalutamide
    • Docetaxel
    France Germany Italy Portugal Spain

  • A study to evaluate the effects of lutetium (177lu) vipivotide tetraxetan in patients with metastatic hormone sensitive prostate cancer receiving androgen deprivation therapy.

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Lutetium (177Lu) Vipivotide Tetraxetan
    Germany Ireland Spain

  • A study testing tulmimetostat with darolutamide or abiraterone in patients with metastatic hormone-sensitive prostate cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Tulmimetostat
    • Abiraterone
    • Darolutamide
    France Germany Hungary Italy Spain

  • Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Relugolix
    • Abiraterone
    • Darolutamide
    Belgium Croatia Czechia Denmark France Ireland +4

  • Study on the Effectiveness of Lutetium (177Lu) Vipivotide Tetraxetan with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Lutetium (177Lu) Vipivotide Tetraxetan
    • Abiraterone Acetate
    • Gozetotide
    Belgium France Ireland Italy The Netherlands Spain

  • Study on the Effectiveness of Abiraterone, Capivasertib, and Enzalutamide in Patients with Metastatic Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-dependent prostate cancer
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Abiraterone Acetate
    • Cabazitaxel
    • Capivasertib
    Belgium Denmark Finland Norway Sweden
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!